NovaBridge Biosciences (NBP) Receivables - Other (2018 - 2023)

NovaBridge Biosciences (NBP) has 6 years of Receivables - Other data on file, last reported at $2.0 million in Q4 2023.

• Quarterly Receivables - Other rose 70.51% year-over-year to $2.0 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $2.0 million (up 70.51% YoY) and the FY2023 annual result came in at $2.0 million, down 53.48% from the prior year.
• Receivables - Other grew to $2.0 million in Q4 2023 per NBP's latest filing, from $1.2 million in the prior quarter.
• Across five years, Receivables - Other topped out at $43.5 million in Q2 2022 and bottomed at $1.2 million in Q4 2022.
• The 5-year median for Receivables - Other is $4.9 million (2021), against an average of $18.0 million.
• The widest annual swing landed in 2020, when Receivables - Other soared 1392.78%; it then plunged 85.6% in 2021.
• Tracing NBP's Receivables - Other over 5 years: stood at $2.3 million in 2019, then soared by 1392.78% to $34.3 million in 2020, then sank by 85.6% to $4.9 million in 2021, then sank by 76.58% to $1.2 million in 2022, then surged by 70.51% to $2.0 million in 2023.
• Per Business Quant, the three latest NBP Receivables - Other figures stand at $2.0 million (Q4 2023), $1.2 million (Q4 2022), and $43.5 million (Q2 2022).

Peer Comparison